FINWIRES · TerminalLIVE
FINWIRES

ASX:NUZ

6 stories mentioning ASX:NUZUpdated 4d ago

Every FINWIRES story that references ASX:NUZ, newest first.

What are analysts saying about ASX:NUZ?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ASX:NUZ?

Treasury

Neurizon Therapeutics Redeems 1 Million Convertible Notes From Obsidian for Over $1 Million; Shares Fall 8%

Neurizon Therapeutics (ASX:NUZ) agreed to redeem 1 million convertible notes held by Obsidian for a total consideration of about $1.2 million, with Obsidian agreeing not to sell Neurizon shares for two months following completion, according to a Thursday Australian bourse filing.Upon completion, Obsidian will hold 750,000 convertible notes, the filing added.Neurizon added that it remains fully funded through to the topline readout of the HEALEY ALS Platform Trial and completion of the study.The company's shares fell past 8% in recent Thursday trade.

ASX:NUZ
Asia

Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%

Neurizon Therapeutics (ASX:NUZ) said the US National Institutes of Health (NIH) has awarded a multimillion-dollar, multi-year grant to support an expanded access protocol (EAP) for its investigational amyotrophic lateral sclerosis (ALS) therapy NUZ-001, according to a Wednesday filing with the Australian bourse.The program is expected to provide up to 200 ALS patients who are ineligible for clinical trials with access to NUZ-001 for up to 96 weeks, alongside the ongoing phase two and three Healey ALS platform trial, per the filing.The company will serve as the regulatory sponsor and provide the drug, while the Healey and AMG Center for ALS will oversee clinical operations, the filing said.The EAP is fully funded by the NIH and is expected to involve about 20 clinical sites across the US, alongside a national virtual site, with enrolment targeted to begin in the first quarter of 2027, subject to regulatory and operational approvals, the filing added.The company's shares jumped 31% in recent Wednesday trade.

ASX:NUZ
Asia

Neurizon Therapeutics Draws Down Over AU$8 Million Under R&D Financing Facility

Neurizon Therapeutics (ASX:NUZ) completed an initial drawdown of around AU$8.3 million under its research and development (R&D) financing facility with Dare Capital Loan Fund, secured against the company's fiscal 2026 R&D tax incentive rebate, according to a Tuesday filing with the Australian bourse.The funds will primarily support the company's continued investment in the pivotal phase two and phase three Healey ALS platform trial, which is now fully recruited and is expected to deliver results in the late second quarter of fiscal 2027, per the filing.The facility provides up to AU$17.5 million in non-dilutive funding, with annual extension options for fiscal 2027 and fiscal 2028 R&D claims, accruing interest at 1.25% per month and repayable upon receipt of the R&D tax incentive refund, the filing added.The company's shares shed nearly 2% in recent Tuesday trade.

ASX:NUZ
Asia

Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment

Neurizon Therapeutics (ASX:NUZ) said it dosed over 50% of participants in the first regimen of a trial evaluating NUZ-001 for the treatment of amyotrophic lateral sclerosis, or ALS, according to a Friday filing with the Australian bourse.ALS is neurological disorder that destroys the nerve cells that control voluntary muscle movement.The company said it surpassed the 50% dosing milestone ahead of schedule, with 129 of 240 participants now dosed, with recruitment momentum also tracking ahead of expectations.Neurizon is well-positioned for last participant dosing in the second quarter of 2027 and for the planned release of top-line results early in the third quarter of 2027.

ASX:NUZ
Asia

Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%

Neurizon Therapeutics (ASX:NUZ) said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis (ALS), according to a Wednesday filing with the Australian bourse.ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.The study is scheduled to start in the third quarter and be completed in the fourth quarter.Neurizon Therapeutics shares gained 3% in recent Wednesday trade.

ASX:NUZ
Asia

Neurizon Therapeutics Raises Nearly AU$3 Million to Reduce Entitlement Offer Shortfall; Shares Fall 7%

Neurizon Therapeutics (ASX:NUZ) received firm commitments to raise AU$2.7 million to help fill the shortfall from its recently completed pro rata non-renounceable entitlement offer, which raised about AU$5.9 million of the targeted AU$17.1 million, leaving a shortfall of around AU$11.3 million, according to a Thursday Australian bourse filing.The company will issue 33.2 million new shares at AU$0.08 each under the shortfall placement, with the shares ranking equally with existing shares, per the filing.Settlement is scheduled for April 20, with allotment taking place on April 21, the filing said.The funds will be used to advance the ongoing clinical development and potential commercialization of its lead candidate NUZ-001, as well as to support general working capital requirements, the filing said.The company's shares fell around 7% in recent Thursday trade.

ASX:NUZ

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:NUZ in your portfolio
WheelAI
WheelAI
Analyze ASX:NUZ options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:NUZ